ISRCTN15770553Active, not recruiting未知
Study of tissue iron uptake in iron-deficient patients receiving intravenous iron replacement therapy: a prospective observational study (STUDY)
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Active, not recruiting
- Sponsor
- niversity of Oxford
- Enrollment
- 13
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Participant is willing and able to give informed consent for participation in the study
- •2. Aged 18 years or above
- •3. Anaemia (haemoglobin less than 120 g/l for women and less than 130g/L for men) and/or confirmed iron deficiency (ferritin less than 100 mcg/l and/or transferrin saturation less than 20%)
- •4. Scheduled to receive intravenous iron for correction of iron deficiency
Exclusion Criteria
- •1. Any MRI incompatible implants (e.g. cardiac, neuro, ocular implants, surgical clips, aneurysm clips, shrapnel/bullets)
- •2. Pregnant or lactating participants
- •3. Acute decompensated heart failure
- •4. Unstable clinical status
- •5. Any other medical conditions which would influence the reliability of the study results determined by the investigators
- •6. Any other contraindication to MRI to be confirmed by the qualified MRI operator, e.g. tattoos containing traces of metal
Investigators
Similar Trials
Completed
Phase 4
Effects of iron deficiency and its treatment on fibroblast growth factor 23 (FGF23) in patients treated with chronic haemodialysis therapy.ACTRN12614000548639Eastern Health Integrated Renal Service40
Active, not recruiting
Not Applicable
‘Intravenous iron treatment in iron deficient patients with pulmonary arterialhypertension' - Treating iron deficiency in PAHEUCTR2010-023233-30-NLVU university medical center30
Recruiting
Not Applicable
Imaging Intravenous IronIron-deficiencyNCT05609318University of Oxford12
Recruiting
Phase 2
Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF)diastolic heart failureNL-OMON54927Vrije Universiteit Medisch Centrum45
Active, not recruiting
Phase 1
Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF)Heart failure with preserved ejection fractionEUCTR2019-003461-17-NLAmsterdam UMC, location VUmc45